Publications

Featured Publications

• SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein

  Keller MD, Harris KM, Jensen-Wachspress MA, Kankate VV, Lang H, Lazarski CA, Durkee-Shock J, Lee PH, Chaudhry K, Webber K, Datar A, Terpilowski M, Reynolds EK, Stevenson EM, Val S, Shancer Z, Zhang N, Ulrey R, Ekanem U, Stanojevic M, Geiger A, Liang H, Hoq F, Abraham AA, Hanley PJ, Cruz CR, Ferrer K, Dropulic L, Gangler K, Burbelo PD, Jones RB, Cohen JI, Bollard CM PMID: 33331927. Free PMC article. Blood 136(25):2905-2917. doi: 10.1182/blood.2020008488 December (2020)

• Successful outcomes of newly diagnosed T lymphoblastic lymphoma: Results from Children's Oncology Group AALL0434

  Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, Hermiston ML, Teachey DT, Perkins SL, Miles RR, Raetz EA, Loh ML, Winick NJ, Carroll WL, Hunger SP, Lim MS, Gross TG, Bollard CM PMID: 32552472 Clinical Trial J Clin Oncol 38(26):3062-3070. doi: 10.1200/JCO.20.00531. Epub June (2020)

• Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: A phase I study

  Hont AB, Cruz CR, Ulrey R, O'Brien B, Stanojevic M, Datar A, Albihani S, Saunders D, Hanajiri R, Panchapakesan K, Darko S, Banerjee P, Fortiz MF, Hoq F, Lang H, Wang Y, Hanley PJ, Dome JS, Bollard CM, Meany HJ PMID: 31356143 Free PMC article. Clinical Trial. J Clin Oncol 37(26):2349-2359. doi: 10.1200/JCO.19.00177. Epub July (2019)

• Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients

  Abraham AA, John TD, Keller MD, Cruz CRN, Salem B, Roesch L, Liu H, Hoq F, Grilley BJ, Gee AP, Dave H, Jacobsohn DA, Krance RA, Shpall EJ, Martinez CA, Hanley PJ, Bollard CM PMID: 31292125 Free PMC article. Blood Adv 3(14):2057-2068. doi: 10.1182/bloodadvances.2019000201 July (2019)

• T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy

  Keller MD, Darko S, Lang H, Ransier A, Lazarski CA, Wang Y, Hanley PJ, Davila BJ, Heimall JR, Ambinder RF, Barrett AJ, Rooney CM, Heslop HE, Douek DC, Bollard CM PMID: 31219185 Free PMC article. Clinical Trial. Br J Haematol 187(2):206-218. doi: 10.1111/bjh.16053. Epub June (2019)

• Engineering the TGFβ Receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for neuroblastoma

  Burga RA, Yvon E, Chorvinsky E, Fernandes R, Cruz CRY, Bollard CM PMID: 31010834 Free PMC article. Clin Cancer Res 25(14):4400-4412. doi: 10.1158/1078-0432.CCR-18-3183. Epub April (2019)

• EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation

  McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM PMID: 30262660 Free PMC article. Clinical Trial. Blood 132(22):2351-2361. doi: 10.1182/blood-2018-07-863654. Epub September (2018)

• HIV-specific T cells generated from naive T cells suppress HIV in vitro and recognize wide epitope breadths

  Patel S, Chorvinsky E, Albihani S, Cruz CR, Jones RB, Shpall EJ, Margolis DM, Ambinder RF, Bollard CM PMID: 29724686 Free PMC article. Mol Ther 26(6):1435-1446. doi: 10.1016/j.ymthe.2018.04.009. Epub April (2018)